

Basic science: (January 2008)

1. Abukhdeir AM, Vitoolol MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C, Konishi Y, Blair BG, Brenner K, Garrett-Mayer E, Carraway H, Bachman KE, Park BH. Tamoxifen-stimulated growth of breast cancer due to p21 loss. *Proc Natl Acad Sci USA* 2008; **105**: 288–293.
2. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, Mohsin SK, O'Connell P, Tsimelzon A, Medina D. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. *Clin Cancer Res* 2008; **14**: 370–378.
3. Arendt LM, Schuler LA. Prolactin drives estrogen receptor- α -dependent ductal expansion and synergizes with transforming growth factor- α to induce mammary tumors in males. *Am J Pathol* 2008; **172**: 194–202.
4. Arlander SJH, Greene BT, Innes CL, Paules RS. DNA protein kinase-dependent G(2) checkpoint revealed following knockdown of ataxia-telangiectasia mutated in human mammary epithelial cells. *Cancer Res* 2008; **68**: 89–97.
5. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M, Liang XL, Hummer AJ, Sima C, Bernstein JL. Variation of breast cancer risk among BRCA1/2 carriers. *JAMA* 2008; **299**: 194–201.
6. Bollet MA, Servant N, Neuvial P, Decraene C, Lebigot I, Meyniel JP, De Rycke Y, Savignoni A, Rigail G, Hupe P, Fourquet A, Sigal-Zafrani B, Barillot E, Thiery JP. High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers. *J Natl Cancer Inst* 2008; **100**: 48–58.
7. Brantley-Sieders DM, Zhuang G, Hicks D, Bin Fang W, Hwang Y, Cates JMM, Coffman K, Jackson D, Bruckheirner E, Muraoka-Cook RS, Chen J. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. *J Clin Invest* 2008; **118**: 64–78.
8. Bretschneider N, Brand H, Miller N, Lowery AJ, Kerin MJ, Gannon F, Denger S. Estrogen induces repression of the breast cancer and salivary gland expression gene in an estrogen receptor α -dependent manner. *Cancer Res* 2008; **68**: 106–114.
9. Bultman SJ, Herschkowitz JI, Godfrey V, Gebuhr TC, Yaniv M, Perou CM, Magnuson T. Characterization of mammary tumors from Brg1 heterozygous mice. *Oncogene* 2008; **27**: 460–468.
10. Caldon C, Lee C, Sutherland R, Musgrove E. Wilms' tumor protein 1: an early target of progesterin regulation in T-47D breast cancer cells that modulates proliferation and differentiation. *Oncogene* 2008; **27**: 126–138.
11. Cascio S, Bartella V, Auriemma A, Johannes GJ, Russo A, Giordano A, Surmacz E. Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1 α . *Oncogene* 2008; **27**: 540–547.
12. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. *Cancer Res* 2008; **68**: 152–161.
13. Chang TW, Chen CC, Chen KY, Su JH, Chang JH, Chang MC. Ribosomal phosphoprotein P0 interacts with GCIP and overexpression of P0 is associated with cellular proliferation in breast and liver carcinoma cells. *Oncogene* 2008; **27**: 332–338.
14. Debies MT, Gest SA, Mathers JL, Mikse OR, Leonard TL, Moody SE, Chodosh LA, Cardiff RD, Gunther EJ. Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19(Arf)/p53 pathway lesions but not p16(Ink4a) loss. *J Clin Invest* 2008; **118**: 51–63.
15. Eckstein N, Servan K, Girard L, Cai D, von Jonquieres G, Jaehde U, Kassack MU, Gazdar AF, Minna JD, Royer HD. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. *J Biol Chem* 2008; **283**: 739–750.

16. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. *J Biol Chem* 2008; **283**: 1026–1033.
17. Frietze S, Lupien M, Silver PA, Brown M. CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. *Cancer Res* 2008; **68**: 301–306.
18. Gao BN, Xie XJ, Huang CX, Shames DS, Chen TTL, Lewis CM, Bian AH, Zhang BF, Olopade OI, Garber JE, Euhus DM, Tomlinson GE, Minna JD. RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. *Cancer Res* 2008; **68**: 22–25.
19. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, Klein CA. Systemic spread is an early step in breast cancer. *Cancer Cell* 2008; **13**: 58–68.
20. Maraqa L, Cummings M, Peter MB, Shaaban AM, Horgan K, Hanby AM, Speirs V. Carcino-embryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. *Clin Cancer Res* 2008; **14**: 405–411.
21. Meijnen P, Peterse JL, Antonini N, Rutgers E, de Vijver MJ. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. *Br J Cancer* 2008; **98**: 137–142.
22. Morishige M, Hashimoto S, Ogawa E, Toda Y, Kotani H, Hirose M, Wei S, Hashimoto A, Yamada A, Yano H, Mazaki Y, Kodama H, Nio Y, Manabe T, Wada H, Kobayashi H, Sabe H. GeP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. *Nat Cell Biol* 2008; **10**: 85–U70.
23. Newman SP, Foster PA, Stengel C, Day JM, Ho YT, Judde JG, Lassalle M, Prevost G, Leese MP, Potter BVL, Reed MJ, Purohit A. STX140 is efficacious *in vitro* and *in vivo* in taxane-resistant breast carcinoma cells. *Clin Cancer Res* 2008; **14**: 597–606.
24. Richard S, Vogel G, Huot ME, Guo T, Muller WJ, Lukong KE. Sam68 haploinsufficiency delays onset of mammary tumorigenesis and metastasis. *Oncogene* 2008; **27**: 548–556.
25. Saal LH, Gruvberger-Saal SK, Persson C, Loevgren K, Jumppanen M, Staaf J, Jonsson G, Pires MM, Maurer M, Holm K, Koujak S, Subramaniam S, Vallon-Christersson J, Olsson H, Su T, Memeo L, Ludwig T, Ethier SP, Krogh M, Szabolcs M, Murty VV, Isola J, Hibshoosh H, Parsons R, Borg A. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. *Nat Genet* 2008; **40**: 102–107.
26. Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PH. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. *Oncogene* 2008; **27**: 366–377.
27. Storci G, Sansone P, Tere D, Tavolari S, Taffurelli M, Ceccarelli C, Guarnieri T, Paterini P, Pariali M, Montanaro L, Santini D, Chieco P, Bonafe M. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. *J Pathol* 2008; **214**: 25–37.
28. Tan BK, Tan LK, Yu K, Tan PH, Lee M, Sii LH, Wong CY, Ho GH, Yeo AWY, Chow PKH, Koong HN, Yong WS, Lim DTH, Ooi L, Soo KC, Tan P. Clinical validation of a customized multiple signature microarray for breast cancer. *Clin Cancer Res* 2008; **14**: 461–469.
29. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang QQ, Bos PD, Gerald WL, Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. *Nature* 2008; **451**: 147–U3.
30. Yang L, Huang JH, Ren XB, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Moses HL. Abrogation of TGF β signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. *Cancer Cell* 2008; **13**: 23–35.

Prepared by
R Sutherland
Cancer Research Program
Garvan Institute of Medical Research
Darlinghurst, NSW, Australia